corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library item: 426

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: news

Eyers J.
PBS politics 'a risk to R&D'
Financial Review 2004 Jun 4


Full text:

PBS politics ‘a risk to R&D’

James Eyers and Eli Greenblat

Financial Review

June 4, 2004

The chief executive of one of the world’s largest drug companies, AstraZeneca, has claimed that international investment in the $12 billion Australian pharmaceutical industry may be at risk unless the pharmaceutical benefits scheme is streamlined.

Tom McKillop, who presides over the drug behemoth that recorded sales of almost $US19billion ($27.3 billion) last year, said this week that AstraZeneca had increased its Australian research and development spending to $22 million a year.

However, the cost focus of the PBS and cost shifting between federal and state governments was making Australia less attractive than lower-cost producers such as China and India.

“If Australia wants to compete in biotechnology and attract pharmaceutical investment, it should be thinking at the same time about the quality of its market,” Sir Tom said, ahead of a round of meetings in Canberra with federal Health Minister Tony Abbott, Industry Minister Ian Macfarlane and opposition health spokeswoman Julia Gillard.

Australia has a reputation for being a cost-competitive country for overseas pharmaceutical companies to conduct their clinical trials. The Australian biotech and pharmaceutical industry reaps annual revenue of more than $1billion, generating 60 per cent of total biotech revenues in the Asia-Pacific region.

But some in the industry fear the rivalry between the states and with Canberra deters investors. Moreover, there are fears that Labor may kill off the free-trade agreement with the US and with it opportunities for greater foreign input into the local drugs industry.

The Labor Party has said it will vote against the free-trade deal if the PBS is undermined, that is, if it means a price surge.

On signing the treaty in Washington last month, Trade Minister Mark Vaile said: “Let’s be clear. There is nothing in the FTA which would increase drug prices in Australia or change the way the PBS operates in relation to drug availability or pricing.”

AusBiotech executive director Tony Coulepis said the umbrella group’s 2000 members believed the FTA gave Australia an unparalleled chance to play a leadership role in the advanced discovery of medicines.

Sir Tom said he was satisfied with the quality of clinical research in Australia, but said the country could get “a bigger slice of the cake” if cost shifting between federal and state governments were eliminated.

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.

Email a Friend








Far too large a section of the treatment of disease is to-day controlled by the big manufacturing pharmacists, who have enslaved us in a plausible pseudo-science...
The blind faith which some men have in medicines illustrates too often the greatest of all human capacities - the capacity for self deception...
Some one will say, Is this all your science has to tell us? Is this the outcome of decades of good clinical work, of patient study of the disease, of anxious trial in such good faith of so many drugs? Give us back the childlike trust of the fathers in antimony and in the lancet rather than this cold nihilism. Not at all! Let us accept the truth, however unpleasant it may be, and with the death rate staring us in the face, let us not be deceived with vain fancies...
we need a stern, iconoclastic spirit which leads, not to nihilism, but to an active skepticism - not the passive skepticism, born of despair, but the active skepticism born of a knowledge that recognizes its limitations and knows full well that only in this attitude of mind can true progress be made.
- William Osler 1909